Alberta Investment Management Corp acquired a new position in Apogee Therapeutics Inc. (NASDAQ:APGE - Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 75,000 shares of the company's stock, valued at approximately $9,955,000. Alberta Investment Management Corp owned about 0.12% of Apogee Therapeutics as of its most recent SEC filing.
Other hedge funds also recently added to or reduced their stakes in the company. TD Asset Management Inc raised its stake in Apogee Therapeutics by 55.3% during the 4th quarter. TD Asset Management Inc now owns 129,290 shares of the company's stock valued at $9,759,000 after buying an additional 46,050 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Apogee Therapeutics by 27.3% in the 4th quarter. Vanguard Group Inc. now owns 2,857,824 shares of the company's stock worth $215,709,000 after buying an additional 612,193 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of Apogee Therapeutics by 13.5% in the first quarter. Bank of America Corp DE now owns 900,871 shares of the company's stock worth $75,826,000 after acquiring an additional 107,176 shares during the period. Pictet Asset Management Holding SA bought a new stake in shares of Apogee Therapeutics in the fourth quarter worth $23,616,000. Finally, Bank of New York Mellon Corp increased its position in Apogee Therapeutics by 7.3% during the first quarter. Bank of New York Mellon Corp now owns 126,757 shares of the company's stock valued at $10,669,000 after acquiring an additional 8,673 shares during the last quarter. 79.04% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Several equities research analysts have recently commented on APGE shares. Truist Financial upped their price target on shares of Apogee Therapeutics from $81.00 to $135.00 and gave the company a "hold" rating in a research report on Thursday. Deutsche Bank Aktiengesellschaft lowered shares of Apogee Therapeutics from a "buy" rating to a "hold" rating and boosted their target price for the company from $116.00 to $135.00 in a research report on Monday, June 22nd. UBS Group cut shares of Apogee Therapeutics from a "buy" rating to a "neutral" rating and upped their target price for the company from $100.00 to $135.11 in a report on Tuesday, June 23rd. BTIG Research downgraded shares of Apogee Therapeutics from a "buy" rating to a "neutral" rating in a research report on Wednesday, August 12th. Finally, Citigroup cut shares of Apogee Therapeutics from a "buy" rating to a "neutral" rating and lifted their price target for the stock from $125.00 to $135.00 in a research note on Tuesday, June 23rd. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, fifteen have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $124.43.
Read Our Latest Stock Analysis on Apogee Therapeutics
Insider Activity at Apogee Therapeutics
In related news, CEO Michael Thomas Henderson sold 20,000 shares of the firm's stock in a transaction on Wednesday, July 8th. The stock was sold at an average price of $133.63, for a total value of $2,672,600.00. Following the completion of the sale, the chief executive officer directly owned 995,987 shares in the company, valued at $133,093,742.81. This trade represents a 1.97% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Carl Dambkowski sold 5,500 shares of Apogee Therapeutics stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $134.17, for a total transaction of $737,935.00. Following the transaction, the insider directly owned 168,498 shares of the company's stock, valued at $22,607,376.66. The trade was a 3.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 162,900 shares of company stock valued at $20,344,950 over the last ninety days. Corporate insiders own 24.30% of the company's stock.
Apogee Therapeutics Price Performance
Shares of APGE stock opened at $134.55 on Monday. The stock has a market cap of $8.37 billion, a P/E ratio of -31.00 and a beta of 0.35. Apogee Therapeutics Inc. has a 52 week low of $35.39 and a 52 week high of $134.88. The company's fifty day simple moving average is $124.42 and its two-hundred day simple moving average is $93.99.
Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last issued its quarterly earnings data on Monday, August 10th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.07) by ($0.07). On average, analysts anticipate that Apogee Therapeutics Inc. will post -4.47 EPS for the current fiscal year.
Apogee Therapeutics Profile
(
Free Report)
Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.
The company's lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.
Read More
Want to see what other hedge funds are holding APGE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Apogee Therapeutics Inc. (NASDAQ:APGE - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Apogee Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Apogee Therapeutics wasn't on the list.
While Apogee Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
